T. Kheoh

发表

Abiraterone and increased survival in metastatic prostate cancer.

Arturo Molina, Tina Cheng, Fred Saad, 2011, The New England journal of medicine.

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.

S. Larson, L. Schwartz, M. Morris, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide

H. Scher, E. Antonarakis, C. Higano, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.

H. Scher, M. Stöckle, D. Rathkopf, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Abiraterone acetate and prednisolone for metastatic castration‐resistant prostate cancer failing androgen deprivation and docetaxel‐based chemotherapy: A phase II bridging study in Korean and Taiwanese patients

Choung-Soo Kim, C. Kwak, Hsi-Chin Wu, 2014, International journal of urology : official journal of the Japanese Urological Association.

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer

A. Tolcher, R. Pili, K. Chi, 2012, Cancer Chemotherapy and Pharmacology.

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis

M. Parmar, M. Sydes, S. Burdett, 2017, European Journal of Cancer.

LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.

Y. Park, D. Ye, B. Alekseev, 2017 .

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.

F. Saad, H. Scher, M. Fleisher, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.

P. Kantoff, S. Larson, M. Morris, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.

H. Scher, J. Bellmunt, Y. Loriot, 2015, European urology.

Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer

H. Scher, P. Mulders, T. Flaig, 2013, Prostate Cancer and Prostatic Disease.

Androgen dynamics and serum PSA in patients treated with abiraterone acetate

H. Scher, C. Ryan, C. Haqq, 2014, Prostate Cancer and Prostatic Disease.

Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial.

H. Scher, E. Small, C. Ryan, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone.

E. Small, G. Bubley, C. Logothetis, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acet

C. Parker, H. Scher, J. Bono, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetat

C. Parker, H. Scher, M. Fleisher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer

P. Neven, M. Campone, D. Hayes, 2016, Clinical Cancer Research.

Clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with a post-treatment circulating tumor cell (CTC) of 0 vs CTC > 0: Post hoc analysis of COU-AA-301.

H. Scher, G. Heller, J. Bono, 2017 .

Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.

H. Scher, D. Cella, C. Sternberg, 2013, European journal of cancer.

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Speci ﬁ c Antigen Across Five Randomized Phase III Clinical Trials

H. Scher, M. Fleisher, R. Dreicer, 2018 .

Precipitation chemistry in east Central Florida from 1978 to 1987

C. Hinkle, T. Kheoh, B. C. Madsen, 1992 .

LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation

J. Christensen, S. Ou, R. Yaeger, 2021, Annals of Oncology.

A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts).

H. Scher, E. Small, D. Danila, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation

S. Ou, J. Christensen, Melissa L. Johnson, 2020, European Journal of Cancer.

Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.

F. Saad, E. Small, D. Rathkopf, 2017, European urology.

Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.

F. Saad, H. Scher, E. Small, 2016, European urology.

Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone.

P. Troncoso, John W. Davis, C. Logothetis, 2019, European urology.

A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.

P. Kantoff, H. Scher, J. Bono, 2013 .

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.

C. Paweletz, J. Christensen, S. Ou, 2022, The New England journal of medicine.

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.

P. Jänne, R. Heist, J. Christensen, 2022, The New England journal of medicine.

806TiPSPARTAN - A RANDOMIZED DOUBLE-BLIND, COMPARATIVE STUDY OF ARN-509 PLUS ANDROGEN DEPRIVATION THERAPY (ADT) VS ADT ALONE IN NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (M0-CRPC).

E. Small, B. Tombal, J. Jassem, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC).

P. Neven, M. Campone, D. Hayes, 2014 .

Abiraterone in metastatic prostate cancer without previous chemotherapy.

F. Saad, E. Basch, J. Carles, 2013, The New England journal of medicine.

Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer

Y. Park, D. Ye, B. Alekseev, 2017, The New England journal of medicine.

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

P. Kantoff, H. Scher, D. Rathkopf, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC

William P. Accomando, T. Mikkelsen, T. Cloughesy, 2018, Neuro-oncology.

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.

D. Dearnaley, C. Parker, H. Scher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

P. Kantoff, E. Small, J. Rosenberg, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

F. Saad, H. Scher, C. Sternberg, 2012, The Lancet. Oncology.

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.

E. Basch, H. Scher, C. Sternberg, 2012, The Lancet. Oncology.

KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.

J. Christensen, Melissa L. Johnson, R. Yaeger, 2022, Journal of Clinical Oncology.

Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

J. Richie, M. Loda, P. Kantoff, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study.

J. Richie, M. Loda, P. Kantoff, 2012 .

Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer

C. Kollmannsberger, K. Chi, T. Griffin, 2015, Journal of clinical pharmacology.

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

F. Saad, J. Carles, K. Miller, 2015, The Lancet. Oncology.

P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation

J. Tabernero, R. Yaeger, S. Kopetz, 2021, Annals of Oncology.

KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation.

T. Mok, E. Felip, S. Dakhil, 2021 .

99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation

P. Jänne, S. Ou, R. Heist, 2021 .

Efficacy and Safety of Abiraterone Acetate in Elderly ( ≥ 75 Years ) Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer

J. Carles, D. Rathkopf, P. Mulders, 2015 .

Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate

H. Scher, C. Logothetis, D. Rathkopf, 2015, Clinical Cancer Research.

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

M. Dowsett, D. Dearnaley, C. Parker, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.

F. Saad, C. Higano, M. Marberger, 2014, European urology.

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy.

H. Scher, C. Cleeland, J. Bono, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302

F. Saad, E. Small, D. Rathkopf, 2016, European urology.

Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.

F. Saad, J. Hainsworth, H. Scher, 2015, European urology.

Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.

D. Petrylak, E. Posadas, S. Tagawa, 2016, European urology.

Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer

H. Scher, M. Fleisher, D. Danila, 2016, European urology.

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.

Tomasz Burzykowski, Arturo Molina, Marc Buyse, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

753OFINAL OVERALL SURVIVAL (OS) ANALYSIS OF COU-AA-302, A RANDOMIZED PHASE 3 STUDY OF ABIRATERONE ACETATE (AA) IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS) WITHOUT PRIOR CHEMOTHERAPY.

F. Saad, K. Miller, C. Sternberg, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response

E. Small, G. Bubley, C. Logothetis, 2011, Clinical Cancer Research.

Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study.

E. Basch, H. Scher, J. Bono, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

F. Saad, J. Hainsworth, J. Carles, 2014, European urology.

Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.

F. Saad, H. Scher, J. Bono, 2013 .

Prognostic Index Model for Progression‐Free Survival in Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone

P. Kantoff, F. Saad, J. Carles, 2017, Clinical genitourinary cancer.

Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetate.

E. Basch, D. Cella, T. Kheoh, 2016, The Journal of community and supportive oncology.

Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.

E. Basch, C. Cleeland, C. Logothetis, 2013, The Lancet. Oncology.

Early CTC decline as a biomarker of response to treatment in castration-resistant prostate cancer (CRPC): Analysis of the COU-AA-301 and IMMC38 trials.

H. Scher, J. Bono, D. Olmos, 2015 .

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer†

P. Neven, M. Campone, D. Hayes, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302).

J. Hainsworth, H. Scher, J. Bono, 2013 .

Carcinogenicity of the anticancer topoisomerase inhibitor, amsacrine, in Wistar rats.

C. Courtney, A. Gough, T. Kheoh, 1996, Fundamental and Applied Toxicology.

Carcinogenicity of the Anticancer Topoisomerase Inhibitor, Amsacrine, in Wistar Rats

C. Courtney, A. Gough, T. Kheoh, 1996 .

Comparison of Results from a Phase 1/2 Study of Lumiliximab (Anti-CD23) in Combination with FCR for Patients with Relapsed CLL with Published FCR Results.

J. Byrd, I. Flinn, T. Kipps, 2006 .

Rituximab Exhibits a Long Half-Life Based on a Population Pharmacokinetic Analysis in Non-Hodgkin’s Lymphoma (NHL) Patients.

N. Frey, A. Joshi, M. Woo, 2007 .

7015 POSTER DISCUSSION Fatigue Improvement/Reduction With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel – Results From the COU-AA-301 Phase 3 Study

H. Scher, J. Bono, C. Sternberg, 2011 .

LBA24 KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation

J. Christensen, S. Ou, R. Yaeger, 2022, Annals of Oncology.

Prognostic index model (PIM) for overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy treated with abiraterone acetate (AA).

P. Kantoff, F. Saad, J. Carles, 2015 .

Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302.

F. Saad, J. Bono, E. Small, 2015 .

Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.

Aliz R. Rao, William P. Accomando, C. Bettegowda, 2020, JAMA oncology.

Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302.

F. Saad, J. Bono, E. Small, 2014 .

Does Gleason score (GS) predict efficacy of abiraterone acetate (AA) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials.

H. Scher, J. Bono, M. Stöckle, 2014 .

Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

J. Carles, H. Scher, J. Bono, 2012 .

Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

J. Carles, H. Scher, E. Small, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

705 ABIRATERONE ACETATE PLUS LOW-DOSE PREDNISONE HAS A FAVORABLE SAFETY PROFILE, IMPROVES SURVIVAL AND PRODUCES PSA AND RADIOGRAPHIC RESPONSES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER DOCETAXEL-BASED CHEMOTHERAPY: RESULTS FROM COU-AA-301, A RANDOMIZED, DOUBLE-BLIND, PLACE

F. Saad, H. Scher, J. Bono, 2011 .

Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy.

H. Scher, C. Sternberg, K. Fizazi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy.

J. Hainsworth, H. Scher, E. Small, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC).

K. Fizazi, Margaret K Yu, N. Tran, 2013 .

Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D).

H. Scher, J. Bono, J. Bellmunt, 2013 .

MP70-11 IMPACT OF PRIOR ENDOCRINE THERAPY ON CLINICAL BENEFIT OF ABIRATERONE ACETATE IN PATIENTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM COU-AA-302

F. Saad, H. Scher, J. Bono, 2014 .

Biological heterogeneity in localized high-risk prostate cancer (LHRPC) from a study of neoadjuvant abiraterone acetate plus leuprolide acetate (LHRHa) versus LHRHa.

P. Troncoso, John W. Davis, C. Logothetis, 2015 .

Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).

F. Saad, H. Scher, C. Logothetis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

P. Jänne, S. Ou, R. Heist, 2020 .

F. Saad, H. Scher, C. Logothetis, 2012, Journal of Clinical Oncology.

A randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy (ADT) versus ADT alone in nonmetastatic castration-resistant prostate cancer (M0-CRPC): The SPARTAN trial.

E. Small, S. Shreeve, Margaret K Yu, 2014 .

1098 ABIRATERONE ACETATE PLUS LOW-DOSE PREDNISONE HAS A FAVORABLE SAFETY PROFILE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER DOCETAXEL-BASED CHEMOTHERAPY: RESULTS FROM COU-AA-301, A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PHASE III STUDY

H. Scher, J. Bono, Robert J. Jones, 2011 .

Exploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).

H. Scher, P. Mulders, T. Flaig, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An indirect treatment comparison (ITC) and cost-effectiveness analysis of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-chemotherapy.

Margaret K Yu, T. Kheoh, Tracy Li, 2014 .

784 THE IMPACT OF ABIRATERONE ACETATE THERAPY ON PATIENT-REPORTED PAIN AND FUNCTIONAL STATUS IN CHEMOTHERAPY-NAÏVE PATIENTS WITH PROGRESSIVE, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER - RESULTS FROM AN UPDATED ANALYSIS

E. Basch, C. Cleeland, C. Logothetis, 2013 .

F. Saad, J. Carles, K. Miller, 2015, The Lancet. Oncology.

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

F. Saad, J. Hainsworth, J. Carles, 2014, European urology.

Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.

F. Saad, H. Scher, E. Small, 2016, European urology.

Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.

J. Carles, D. Rathkopf, P. Mulders, 2015, The Journal of urology.

Association of Radiographic Progression-Free Survival (RPFS) Adapted from Prostate Cancer Working Group 2 (PCWG2) Consensus Criteria (APCWG2) with Overall Survival (OS) in Patients (PTS) with Metastatic Castration-Resistant Prostate Cancer (MCRPC): Results from COU-AA-302

S. Larson, M. Morris, H. Scher, 2012 .

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.

S. Larson, L. Schwartz, M. Morris, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.

D. Dearnaley, C. Parker, H. Scher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI).

P. Neven, M. Campone, D. Hayes, 2014 .

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial

Z. Wainberg, P. Kasi, T. Kheoh, 2024, Nature medicine.

Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.

V. Velcheti, Zhaoyuan Fang, Minglei Shi, 2024, Cancer cell.

Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer

V. Velcheti, Fei Li, A. Aguirre, 2023, bioRxiv.

Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.

H. Scher, J. Bellmunt, Y. Loriot, 2015, European urology.

A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy.

I. Tannock, J. Bono, F. Vera-Badillo, 2014 .

F. Saad, E. Small, D. Rathkopf, 2017, European urology.